Drugmakers raise prices on dozens of meds to start July: analyst

艾伯维、罗氏、赛诺菲等药企纷纷在美国提高药品价格,特朗普称提价可耻

2019-07-11 18:30:00 FiercePharma

本文共1064个字,阅读需3分钟

It’s not uncommon for drugmakers to raise prices on big-selling meds to start each year and at each year's halfway point. So as the calendar turned to July, many companies marked the occasion with price increases in an indication that political pressure against pharma's price hikes may be waning. So far in July, drugmakers including AbbVie, Roche’s Genentech, Eli Lilly, GlaxoSmithKline and Sanofi have raised prices on at least 83 medicines, Wells Fargo analyst David Maris wrote in a note. He cited MediSpan PriceRx data in his reporting and only tracked price hikes from a group of big and specialty pharma companies. The figure compares with eight price hikes for the same group last year. Market watchers may remember Pfizer’s mid-year price hikes in 2018 that caused a headache for the industry. After the company raised dozens of prices, President Donald Trump tweeted that the pharma giant and others “should be ashamed” of their moves. After a call between Pfizer’s then-CEO Ian Read, Trump and HHS secretary Alex Azar, the company agreed to defer the increases. Now, price hikes seem to be attracting less attention, Maris wrote. “To us it appears now that the criticism from politicians and the president has quieted down, companies are more aggressively and broadly pursuing drug price increases again,” he wrote. “We are not so confident that the lull in criticism will continue and could foresee more negative headlines in the coming months." In July, Novartis’ Sandoz raised prices on six products by 9.9%; AbbVie raised prices on blood cancer treatment Venclexta by 5%; Genentech raised prices on a range of products by 1.5% to 3%; Amneal instituted its own set of 9.9% price hikes; Eli Lilly raised prices for cancer drugs Cyramza, Alimta and Erbitux by 2.5%; and Merck raised prices on HIV therapy Insentress by 5%. The July increases followed 35 in June among the group, Maris wrote. Those increases ranged from 1.5% to 909% from Teva, which hiked the price on its Desmopressin Acetate Injection Solution. In a follow-up note, Maris wrote that Teva stopped selling the drug in 2012, and relaunched last month at what it thought was an appropriate price. Pharma’s practice of routinely raising its prices has generated intense pushback in recent years, and the Trump Administration has been working to fight high prices as Congress mulls its own measures. The administration originally forced drug prices into TV ads, but a federal judge recently struck down the rule. The administration is also working to tweak drug rebating, among other proposals. Amid administration and Congressional efforts, prices continue to climb. In addition to the mid-year increases, drugmakers instituted a range of price hikes to start the year.
对于制药商来说,从每年年初到每年中期提高畅销药品的价格并不罕见。因此,随着时间转到7月,许多公司都以提价来纪念这一时刻,表明针对制药公司提价的政治压力可能正在减弱。 富国银行(Wells Fargo)分析师David Maris在一份报告中写道,7月迄今,包括艾伯维(AbbVie)、罗氏(Roche)基因泰克(Genentech)、礼来(Eli Lilly)、葛兰素史克(GlaxoSmithKline)和赛诺菲(Sanofi)在内的制药商至少上调了83种药品的价格。他在报告中引用了MediSpan PriceRx的数据,只追踪了一些大型和专业制药公司的提价。这一数字与去年同期的8次提价形成了对比。 市场观察人士可能还记得辉瑞在2018年的年中价格上涨,这让该行业头疼。在公司提高了几十个价格之后,唐纳德·特朗普总统在推特上说,制药巨头和其他公司应该为他们的行动感到羞耻。在辉瑞当时的首席执行官伊恩·里德(IanRead)、特朗普(Trump)和卫生和公众服务部(HHS)秘书亚历克斯·阿扎尔(AlexAzar)通了电话后,该公司同意推迟加价。 现在,物价上涨似乎没有引起那么多关注,Maris写道。 他写道:“在我们看来,来自政界人士和总统的批评似乎已经平息下来,制药公司正更积极、更广泛地再次追求药品价格上涨。”我们不太相信批评的平静会持续下去,而且未来几个月可能会出现更多负面新闻。 7月份,诺华的Sandoz将6种产品的价格提高了9.9%;Abbvie将血癌治疗Venclexta的价格提高了5%;Genentech将一系列产品的价格提高了1.5%至3%;Amneal自己也提高了9.9%的价格;Eli Lilly提高了癌症药物Cyramza,Alimt的价格。A和Erbitux分别上涨了2.5%和5%,默克公司提高了艾滋病治疗费用。 Maris写道,7月份的增长是在6月份的35次之后。Teva的提价幅度从1.5%到909%不等,后者提高了其醋酸去氨加压素注射液的价格。在一份后续报告中,Maris写道Teva在2012年停止销售这种药物,并在上个月以它认为合适的价格重新推出。 近年来,制药公司经常提高价格的做法引起了强烈的回击,特朗普政府一直在努力与高价格作斗争,因为国会正在考虑自己的措施。政府最初强迫药品价格进入电视广告,但最近一位联邦法官否决了这项规定。除了其他提议外,美国政府还在努力调整毒品再平衡。 在政府和国会的努力下,油价继续攀升。除了年中价格上涨外,制药商还在今年年初采取了一系列提价措施。

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文